Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: A propensity score analysis Journal Article

   

Authors:	Koerkamp, B. G.; Sadot, E.; Kemeny, N. E.; Gönen, M.; Leal, J. N.; Allen, P. J.; Cercek, A.; DeMatteo, R. P.; Kingham, T. P.; Jarnagin, W. R.; D’Angelica, M. I.
Article Title:	Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: A propensity score analysis
Abstract:	Purpose: To investigate whether perioperative hepatic arterial infusion pump chemotherapy (HAI) was associated with overall survival (OS) in patients who had a complete resection of colorectal liver metastases (CLM). Methods: Patients who underwent a complete resection of CLM between 1992 and 2012 were included from a single-center prospectively maintained database. All patients who received HAI also received perioperative systemic chemotherapy. Propensity score analysis was used to match patients for seven known prognostic factors. Results: A total of 2,368 consecutive patients underwent a complete resection of CLM, with a median followup of 55 months. The median OS for patients with HAI (n = 785) was 67 months versus 44 months without HAI (n = 1,583; P, .001), despite more advanced disease in the HAI group. OS at 10 years was 38.0% versus 23.8% without HAI. For patients who received modern systemic chemotherapy (n = 1,442), the median OS was 67 months with HAI and 47 months without HAI (P, .001). The hazard ratio adjusted by propensity score demonstrated longer OS with HAI: 0.67 (95% CI, 0.59 to 0.76; P, .001). A pronounced difference in median OS was found for patients with node-negative colorectal cancer (129 months with HAI v 51 months without; P, .001) and a low clinical risk score of 0 to 2 points (89 months with HAI v 53 months without; P, .001). Conclusion: Patients who received HAI had a median OS of approximately 2 years longer than patients without HAI. The strong association was independent of the use of modern systemic chemotherapy and remained in propensity score analysis. Patients with node-negative primary tumors or a low clinical risk score seemed to benefit most from HAI. © 2017 by American Society of Clinical Oncology.
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	17
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-06-01
Start Page:	1938
End Page:	1944
Language:	English
DOI:	10.1200/jco.2016.71.8346
PROVIDER:	scopus
PMCID:	PMC5466010
PUBMED:	28426374
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021709047&doi=10.1200%2fJCO.2016.71.8346&partnerID=40&md5=b1b86eee872bc2be1ff9b68ffdda7ece
Notes:	Article -- Export Date: 2 August 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/114136